{"id":"62b50ca2ec86","type":"article","url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","title":"Edoxaban 15 mg naar nierfunctie bij zeer oude AF: ELDERCARE subanalyse","title_en":"Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":["sacubitril-valsartan"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.057190","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.121.057190","authors":["Tetsuro Yoshida","Akihiro Nakamura","Junichi Funada","Mari Amino","Wataru Shimizu","Masayuki Fukuzawa","Saori Watanabe","Takuya Hayashi","Takeshi Yamashita","Ken Okumura","Masaharu Akao"],"significance":6,"published":"2022-03-01","source_date":"2022-03-01","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/doac-versus-vka-keuze/"],"congress":"","summary_en":"This ELDERCARE subanalysis confirmed that low-dose edoxaban (15 mg) maintains its favorable efficacy-safety profile across different levels of renal function in very elderly AF patients.","created":"2026-07-03T10:29:39Z","updated":"2026-07-03T13:28:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ELDERCARE subanalyse van edoxaban 15 mg gestratificeerd naar nierfunctie bij zeer oude AF-patiënten.","abstract_original":""}